The study concluded that the adjuvant group had a significant 74% decreased risk of biochemical prostate cancer recurrence compared to men who had only surgery.
Metastatic Prostate Cancer (Copay) now open at Patient Advocate Foundation Co-Pay Relief.
Prostate Cancer (Copay) now open at Patient Advocate Foundation Co-Pay Relief.
We should note that the two scans performed equally well in men who had their recurrence only in the prostate bed. However, the trial also showed that the PSMA PET scan detected more cancerous pelvic lymph nodes and non-regional metastases.
Research shows that aloe vera alone is ineffective and may worsen skin reactions from radiation treatment. Research has shown that the cleansing the skin daily with mild moisturizing soaps is most beneficial.
Update on the Guidelines for the Prevention and Management of Osteonecrosis of the Jaw
We are happy to announce that on July 30, 2019, the Food and Drug Administration (FDA) approved a new drug, darolutamide (NUBEQA®, Bayer HealthCare Pharmaceuticals Inc.) for the treatment of men with non-metastatic castration-resistant prostate cancer.
In summary, these results demonstrate worse outcomes in men with germline BRCA2 and CHEK2 mutations compared with men without these mutations when treated with standard first-line ADT with LHRH analogs.
This study did demonstrate that the level of PSMA expression of a man’s prostate cancer, the stronger the association with the likelihood of their having a PSA response.
There has long been a discussion about the possible effects of using testosterone as a treatment for men with advanced metastatic prostate cancer. In a poster presentation at ASCO 2019, it was shown that there are androgen receptor changes in the circulating-tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with high-dose testosterone.
We can conclude that it isn’t necessary for all men taking Zytiga plus prednisone to continue ADT, but some men will see an increase in their testosterone levels, warranting close monitoring and adding back ADT to their treatment.
After a median follow-up of 14.4 months, the men who had Xtandi along with ADT experienced an improved radiographic progression-free survival advantage over those who had only ADT, regardless of their prior treatment.
Findings confirm the better strategy for salvage therapy after failed surgery for prostate cancer is ADT along with radiotherapy,
The ARAMIS Trial showed that darolutamide increased overall survival for men with prostate cancer, it delayed the time to the use of cytotoxic chemotherapy as well as improving the important quality of life (QoL) measures of time to pain progression, and time to developing a symptomatic skeletal-related event.
The trial found that 80% of men with metastatic hormone-sensitiveprostate cancer who received enzalutamide (Xtandi) along with standard-of-care treatment (ADT) were alive after three years, compared with just 72% of men who received other nonsteroidal antiandrogens along with standard ADT therapy.
Make sure that you and your doctor use the bone-protecting approved medications (zoledronic acid or denosumab), especially for at least three weeks before using Xofigo (Radium-223).
Deferred hormone therapy (ADT) for in relapsing M0 (negative scans) prostate cancer patients is associated with prolonged overall survival (OS) measured from the time of local treatment, comparable to OS with salvage ADT in the contemporary experience.
The use of apalutamide (Erleada) improved radiographic progression-free survival with a 52% reduction in risk of death or radiographic progression; that benefit was observed across all subgroups analyzed in the TITAN TRIAL for men with progressing prostate cancer that is still hormone sensitive. The median radiographic progression-free survival was not reached in the apalutamide group and was 22.1 months in the placebo group.
The Man Cave is a unique patient care model that combines educational resources, emotional support, and the latest medical technology. They are creating sports-themed facilities where men can feel at ease, complete with a team of friends, medical professionals, educators, and advocates ready to help them take control of their healthcare journey.
The practice of “surprising” patients with unexpected, exorbitant bills needs to stop and insurance companies need to become responsible for reasonable out of network medical expenses
As early as 2013, we have known that a lower baseline prostate-specific antigen (PSA) is associated with a higher overall survival benefit from Provenge (sipuleucel-T)